# Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC

> **NCT06055738** · PHASE2 · RECRUITING · sponsor: **Tang-Du Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Locally Advanced Cervical Cancer

## Interventions

- **DRUG:** Zimberelimab
- **DRUG:** Albumin-bound Paclitaxel
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT06055738
- **Lead sponsor:** Tang-Du Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-09
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06055738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06055738, "Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT06055738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*